85 related articles for article (PubMed ID: 27584069)
1. Assessing the Educational Needs of Urologists Managing Patients With Castration-Resistant Prostate Cancer: A Multiyear Study.
Barlett MM; Carrick TA; Lowrance WT; Freedland SJ
J Contin Educ Health Prof; 2016; 36 Suppl 1():S42-3. PubMed ID: 27584069
[No Abstract] [Full Text] [Related]
2. Castration-resistant prostate cancer: where we stand in 2013 and what urologists should know.
Heidenreich A; Pfister D; Merseburger A; Bartsch G;
Eur Urol; 2013 Aug; 64(2):260-5. PubMed ID: 23706522
[No Abstract] [Full Text] [Related]
3. [Role of urologists in the era of new treatment modalities for CRPC in Japan].
Ozono S
Gan To Kagaku Ryoho; 2014 Jul; 41(7):823-6. PubMed ID: 25131867
[TBL] [Abstract][Full Text] [Related]
4. Management of patients with castration-resistant prostate cancer (CRPC): results of an Italian survey using the delphi method.
Terrone C; Berruti A; Papotti M; Vavassori V; Sciarra A
Tumori; 2016 Oct; 102(5):514-520. PubMed ID: 26166221
[TBL] [Abstract][Full Text] [Related]
5. Current management of advanced and castration resistant prostate cancer.
Gomella LG; Petrylak DP; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
[TBL] [Abstract][Full Text] [Related]
6. Austrian recommendations on Targeted Hormone Therapy for metastatic, castration-resistant prostate cancer.
Ponholzer A; Loidl W; Bektic J; Dorfinger K; Hruby S; Jeschke K; Kramer G; Krause S; Ludvik G; Remzi M; Roider M; Stoiber F
Wien Klin Wochenschr; 2016 Feb; 128(3-4):156-63. PubMed ID: 26831188
[TBL] [Abstract][Full Text] [Related]
7. The economics of abiraterone acetate for castration-resistant prostate cancer.
Dellis A; Papatsoris AG
Expert Rev Pharmacoecon Outcomes Res; 2014 Apr; 14(2):175-9. PubMed ID: 24564607
[TBL] [Abstract][Full Text] [Related]
8. A urologic oncology roundtable discussion: how to choose among the available therapies for the treatment of castration-resistant prostate cancer.
Ryan C; Shore ND; Concepcion R
Postgrad Med; 2013 Nov; 125(6):114-6. PubMed ID: 24200767
[TBL] [Abstract][Full Text] [Related]
9. [Molecular biology of castration-resistant prostate cancer].
Doucet L; Terrisse S; Gauthier H; Pouessel D; Le Maignan C; Teixeira L; Culine S
Bull Cancer; 2015 Jun; 102(6):497-500. PubMed ID: 26028493
[TBL] [Abstract][Full Text] [Related]
10. [ASC-J9 for castration-resistant prostate cancer].
Yamashita S; Arai Y
Nihon Rinsho; 2014 Dec; 72(12):2126-9. PubMed ID: 25518345
[TBL] [Abstract][Full Text] [Related]
11. Practice patterns and predictors of followup imaging after a negative bone scan in men with castration resistant prostate cancer: results from the SEARCH database.
Sourbeer KN; Howard LE; Moreira DM; Amarasekara HS; Chow LD; Cockrell DC; Hanyok BT; Pratson CL; Kane CJ; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Hernandez RK; Freedland SJ
J Urol; 2015 Apr; 193(4):1232-8. PubMed ID: 25463986
[TBL] [Abstract][Full Text] [Related]
12. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
[TBL] [Abstract][Full Text] [Related]
13. The hallmarks of castration-resistant prostate cancers.
Katsogiannou M; Ziouziou H; Karaki S; Andrieu C; Henry de Villeneuve M; Rocchi P
Cancer Treat Rev; 2015 Jul; 41(7):588-97. PubMed ID: 25981454
[TBL] [Abstract][Full Text] [Related]
14. Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer.
Ren S; Liu Y; Xu W; Sun Y; Lu J; Wang F; Wei M; Shen J; Hou J; Gao X; Xu C; Huang J; Zhao Y; Sun Y
J Urol; 2013 Dec; 190(6):2278-87. PubMed ID: 23845456
[TBL] [Abstract][Full Text] [Related]
15. The treatment patterns of castration-resistant prostate cancer in Japan, including symptomatic skeletal events and associated treatment and healthcare resource use.
Uemura H; DiBonaventura M; Wang E; Ledesma DA; Concialdi K; Aitoku Y
Expert Rev Pharmacoecon Outcomes Res; 2017 Oct; 17(5):511-517. PubMed ID: 28277852
[TBL] [Abstract][Full Text] [Related]
16. Pre-chemotherapy abiraterone acetate. A proposal of a treatment algorithm in castration resistant prostate cancer.
Arrabal-Martín M; Anglada-Curado F; Cózar-Olmo JM; Soler-Martínez J; Moreno-Jiménez J; Castiñeiras-Fernández J; Ledo-Cepero MJ; Beardo-Villar P; Requena-Tapia MJ; Zuluaga-Gómez A;
Actas Urol Esp; 2014 Jun; 38(5):327-33. PubMed ID: 24342031
[TBL] [Abstract][Full Text] [Related]
17. Navigating Treatment of Metastatic Castration- Resistant Prostate Cancer: Nursing Perspectives.
dela Rama F; Pratz C
Clin J Oncol Nurs; 2015 Dec; 19(6):723-32. PubMed ID: 26583636
[TBL] [Abstract][Full Text] [Related]
18. Management of castration-resistant prostate cancer: a call to urologists.
Fitzpatrick JM
BJU Int; 2012 Sep; 110(6):772-4. PubMed ID: 22882501
[No Abstract] [Full Text] [Related]
19. Advances in systemic therapies for metastatic castration-resistant prostate cancer.
Pant MK; Abughaban A; Aragon-Ching JB
Future Oncol; 2014 Nov; 10(14):2213-26. PubMed ID: 25471035
[TBL] [Abstract][Full Text] [Related]
20. [Concomitant use of abiraterone acetate and triptorelin in patients with castration-resistant prostate cancer].
Rapoport LM; Bezrukov EA; Kondrashina AV
Urologiia; 2016 Feb; (1):58-61. PubMed ID: 28247705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
